Performance of NLP-based^†† Algorithm by Patient Characteristic.

<p>Performance of NLP-based<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0153103#t002fn004" target="_blank">^††</a> Algorithm by Patient Characteristic.</p

Correlates of Smoking in Overall Group^*.

<p>Correlates of Smoking in Overall Group<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0153103#t003fn001" target="_blank">^*</a>.</p

Patient Characteristics^*.

<p>Patient Characteristics<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0153103#t001fn001" target="_blank">^*</a>.</p

Demographic characteristics of NHANES participants.

<p>Demographic characteristics of NHANES participants.</p

Trends in food insecurity prevalence among those with and without: Diabetes, hypertension, and obesity (top), coronary heart disease and congestive heart failure (middle) and uncontrolled hemoglobin A1c, low-density lipoprotein cholesterol, and hypertension (bottom).

<p>Trends in food insecurity prevalence among those with and without: Diabetes, hypertension, and obesity (top), coronary heart disease and congestive heart failure (middle) and uncontrolled hemoglobin A1c, low-density lipoprotein cholesterol, and hypertension (bottom).</p

Trends in SNAP participation among those income-eligible, by NHANES wave.

<p>Trends in SNAP participation among those income-eligible, by NHANES wave.</p

Food insecurity trends by NHANES wave.

<p>Food insecurity trends by NHANES wave.</p

Baseline unadjusted and propensity score weighted characteristics of new glargine and NPH insulin users.

<p>Note: Only patients with nonmissing values for all covariates are included. All variables were included in the logistic regression for propensity score.</p><p>Baseline unadjusted and propensity score weighted characteristics of new glargine and NPH insulin users.</p

Association between long-acting insulin use and cancer for new users by dose category (As-Treated Analysis).

<p>Hazard ratios and their 95% CIs were obtained from Cox proportional hazards models adjusted for gender and age at the start of the dose category.</p><p>CI, confidence interval; HR, hazard ratio; IR, incidence rate per 100 person-years.</p><p>Patients were followed until the first occurrence of one of the following events: the patient switched treatments or augmented with another long-acting insulin, the patient developed cancer, death, the study ended, or one year after the patient’s last visit in the database.</p><p>Only patients with dose data for the insulin treatment that they initiated are included in this analysis.</p><p>Association between long-acting insulin use and cancer for new users by dose category (As-Treated Analysis).</p

Cancer free survival curves in new glargine and NPH insulin users.

<p>Cancer free survival curves in new glargine and NPH insulin users.</p